Guardion Health Sciences (GHSI) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardion Health Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GHSI shares.
View GHSI analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12-month price targets for Guardion Health Sciences' stock. Their GHSI share price forecasts range from $37.50 to $37.50. On average, they expect the company's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 507.8% from the stock's current price.
View analysts price targets for GHSI or view top-rated stocks among Wall Street analysts.

Guardion Health Sciences' stock was trading at $7.2550 on January 1st, 2023. Since then, GHSI shares have decreased by 15.0% and is now trading at $6.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GHSI earnings forecast.

Guardion Health Sciences, Inc. (NASDAQ:GHSI) announced its quarterly earnings data on Monday, August, 12th. The company reported ($42.00) earnings per share (EPS) for the quarter. The business earned $0.26 million during the quarter. Guardion Health Sciences had a negative trailing twelve-month return on equity of 51.17% and a negative net margin of 76.69%.

Guardion Health Sciences shares reverse split on the morning of Sunday, January 8th 2023. The 1-50 reverse split was announced on Sunday, January 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, January 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardion Health Sciences investors own include iBio (IBIO), Biocept (BIOC), Onconova Therapeutics (ONTX), Heat Biologics (HTBX), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Ocugen (OCGN), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX) and FuelCell Energy (FCEL).

(GHSI) raised $6 million in an IPO on Friday, April 5th 2019. The company issued 1,500,000 shares at $4.00 per share. WallachBeth Capital and Westpark Capital acted as the underwriters for the IPO.

Guardion Health Sciences trades on the NASDAQ under the ticker symbol "GHSI."

Guardion Health Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.80%), BlackRock Inc. (0.79%) and Barclays PLC (0.39%). Insiders that own company stock include Bradley Louis Radoff and Bret Scholtes.
View institutional ownership trends.

Shares of GHSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GHSI stock can currently be purchased for approximately $6.17.

Guardion Health Sciences (NASDAQ:GHSI) has a market capitalization of $7.84 million and generates $11.05 million in revenue each year.

Guardion Health Sciences' mailing address is 15150 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The official website for the company is www.guardionhealth.com. The company can be reached via phone at (800) 873-5141, via email at matthew@plrinvest.com, or via fax at 858-630-5543.